Cargando…
Betting on improved cancer immunotherapy by doubling down on CD134 and CD137 co-stimulation
The ability of T cells to recognize a vast array of antigens enables them to destroy tumor cells while inflicting minimal collateral damage. Nevertheless, tumor antigens often are a form of self-antigen, and thus tumor immunity can be dampened by tolerance mechanisms that evolved to prevent autoimmu...
Autores principales: | Adler, Adam J., Vella, Anthony T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Landes Bioscience
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3583935/ https://www.ncbi.nlm.nih.gov/pubmed/23482891 http://dx.doi.org/10.4161/onci.22837 |
Ejemplares similares
-
A mathematical model of combined CD8 T cell costimulation by 4-1BB (CD137) and OX40 (CD134) receptors
por: Konstorum, Anna, et al.
Publicado: (2019) -
CD134/CD137 Dual Costimulation-Elicited IFN-γ Maximizes Effector T Cell Function but Limits Treg Expansion
por: Rose, Marie-Clare St., et al.
Publicado: (2013) -
Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies
por: Glez-Vaz, Javier, et al.
Publicado: (2022) -
Correction: Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies
Publicado: (2023) -
Immunogenicity risk assessment for biotherapeutics through in vitro detection of CD134 and CD137 on T helper cells
por: Cohen, Sivan, et al.
Publicado: (2021)